Wainwright Initiates Monte Rosa With a Buy as MRT-8102 Phase 1 Data Arrive
Wainwright cites a $565M enterprise value, cash into 2029, and multiple trials.
/ 185 items
#XY Analyst Up/Down↓
Whitehawk Gets a Buy From Stifel as Analysts Bet on a More Stable Cancer Drug
Three ADC trials and cash into 2028 are the setup.
Stifel Puts Buy Rating on Achieve After Manufacturing and Capital Reset
Stifel initiates Achieve Life Sciences at Buy with an $18 target, citing a manufacturing, leadership, and capital reset ahead of a 2026 NDA resubmission.
Citi Says Moderna Looks Too Expensive After Cancer-Vaccine Rally
Citi says Moderna’s rally after the INTerpath-001 melanoma win pushed its market value near Regeneron’s despite weaker near-term earnings.
Lexicon Surges as Cantor Sees an Unencumbered Path in HCM
Cantor initiates LXRX Overweight with an $8 target on sotagliflozin’s fully enrolled Phase 3 SONATA-HCM trial and a Q1 2027 readout.
Jefferies Initiates Q32 Bio at Buy With $29 Target on Alopecia Potential
The firm points to bempikibart in severe alopecia, a 1H 2027 Phase 3 start, and a stronger cash runway.